Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a

Abstract Background Significant interindividual variability in tumor necrosis factor inhibitor (TNFi) drug levels and anti-drug antibody formation contribute to treatment failure and disease flares in rheumatoid arthritis (RA). Proactive therapeutic drug monitoring (TDM), individualized drug dosing based on regular assessments of serum drug levels and anti-drug antibodies (ADAb), may improve TNFi therapy. However, evidence regarding the use of TDM in subcutaneous (SC) TNFi treatment is lacking. This study evaluates whether a treatment strategy incorporating TDM is superior to standard of care in maintaining sustained disease control without flares in RA patients treated with SC TNFi (adalimumab). Methods RA-DRUM is a multicenter, multinational, randomized, two-arm, parallel-group, open superiority trial. Adult participants with RA in remission or low disease activity on therapy with standard dose of a SC TNFi (adalimumab) for 3–24 months with indication for continuation of treatment are allocated to administration of TNFi based on proactive TDM (TDM group) or administration of TNFi based on standard of care without knowledge of drug or ADAb levels (standard of care group). In the TDM group, dosing will be adjusted with the aim of keeping the serum adalimumab 5.0–12.0 mg/L. The primary endpoint is sustained disease control without flare over the 18 months follow-up period. Discussion TNFi is a cornerstone in the treatment of RA and other immune-mediated inflammatory diseases, and there is a strong rationale to achieve the best possible results of the drug. TDM has been suggested as a strategy to improve treatment with TNFi therapy. This randomized trial comparing TDM to standard of care for maintaining sustained disease control will fill a clinically important knowledge gap of high relevance for the management of a common disease with a potentially disabling disease course. Trial registration EU CT No: 2023-510184-35-00, registered on January 31st, 2024. ClinicalTrials.gov NCT06440629, registered on May 23th, 2024, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510184-35-00 .

Authors

Institutions

Publication Details

Journal
Trials
Published
2026-11-14
DOI
https://doi.org/10.1186/s13063-026-10090-1
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a

Espen Andre Haavardsholm, Katerina Chatzidionysiou, Eirik Klami Kristianslund, Marthe Kirkesæther Brun et al.
Trials
Rheumatoid Arthritis Research and Therapies
article

Effect of proactive therapeutic drug monitoring on maintenance of sustained disease control in adults with rheumatoid arthritis on a subcutaneous TNF inhibitor: the Rheumatoid Arthritis therapeutic DRUg Monitoring trial (RA-DRUM)—study protocol for a

Espen Andre Haavardsholm, Katerina Chatzidionysiou, Eirik Klami Kristianslund, Marthe Kirkesæther Brun, Silje Watterdal Syversen, Catalin Codreanu, Siri Lillegraven, Johanna Elin Gehin, Guro Løvik Goll, Daniel Aletaha, Michele Bombardieri, Ingrid Jyssum, Nils Bolstad, Helga Lechner-Radner, Joseph Sexton, Costantino Pitzalis, Camilla Skancke Mørstad
article en

Abstract

Abstract Background Significant interindividual variability in tumor necrosis factor inhibitor (TNFi) drug levels and anti-drug antibody formation contribute to treatment failure and disease flares in rheumatoid arthritis (RA). Proactive therapeutic drug monitoring (TDM), individualized drug dosing based on regular assessments of serum drug levels and anti-drug antibodies (ADAb), may improve TNFi therapy. However, evidence regarding the use of TDM in subcutaneous (SC) TNFi treatment is lacking. This study evaluates whether a treatment strategy incorporating TDM is superior to standard of care in maintaining sustained disease control without flares in RA patients treated with SC TNFi (adalimumab). Methods RA-DRUM is a multicenter, multinational, randomized, two-arm, parallel-group, open superiority trial. Adult participants with RA in remission or low disease activity on therapy with standard dose of a SC TNFi (adalimumab) for 3–24 months with indication for continuation of treatment are allocated to administration of TNFi based on proactive TDM (TDM group) or administration of TNFi based on standard of care without knowledge of drug or ADAb levels (standard of care group). In the TDM group, dosing will be adjusted with the aim of keeping the serum adalimumab 5.0–12.0 mg/L. The primary endpoint is sustained disease control without flare over the 18 months follow-up period. Discussion TNFi is a cornerstone in the treatment of RA and other immune-mediated inflammatory diseases, and there is a strong rationale to achieve the best possible results of the drug. TDM has been suggested as a strategy to improve treatment with TNFi therapy. This randomized trial comparing TDM to standard of care for maintaining sustained disease control will fill a clinically important knowledge gap of high relevance for the management of a common disease with a potentially disabling disease course. Trial registration EU CT No: 2023-510184-35-00, registered on January 31st, 2024. ClinicalTrials.gov NCT06440629, registered on May 23th, 2024, https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-510184-35-00 .

Trials
Oslo University Hospital (NO), Karolinska University Hospital (SE), Carol Davila University of Medicine and Pharmacy (RO), Queen Mary University of London (GB), University of Oslo (NO), Karolinska Institutet (SE), Diakonhjemmet Hospital (NO), Medical University of Vienna (AT)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon